Official EU label nameGlossary entry 27472

SQUALENE

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence
Markets checked
13
Markets with evidence
0
Evidence gaps
13
Resolved identifiers
2

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:111-02-4
EC:203-826-1
Ingredient index records:
SQUALENE
Cosmetic functions: ANTISTATIC, HAIR CONDITIONING, REFATTING, SKIN CONDITIONING, SKIN CONDITIONING - EMOLLIENT

2,6,10,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaene

1 matched or reported name
SQUALENE

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
No local match0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
No local match0
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand
NZ
No local match0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
No local match0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
No local match0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
No local match0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
No local match0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
No local match0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
No local match0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
No market rows match this filter.

Chemical identity and properties

PubChem 2D chemical structure for CAS 111-02-4
CAS 111-02-4PubChem CID 638072

Squalene

IUPAC name
(6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene
Molecular formula
C30H50
Molecular weight
410.7 g/mol
Exact mass
410.391251595 Da
XLogP3
11.6
Topological polar surface area
0.0 Ų
Hydrogen-bond donors
0
Hydrogen-bond acceptors
0
Covalent units
1
Defined stereocentres
0

Also known as

Spinacenetrans-SqualeneAll-trans-SqualeneSpinacenNikko Squalane EXSuper SqualeneSqualen(All-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
16 more reported names
7QWM220FJHCHEBI:154402,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaene2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (all-E)-2,6,10,14,18,22-tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (6E,10E,14E,18E)-2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (2E,6E,10E,14E,18E)-RefChem:6257203-826-1Supraene(E)-Squalene(E,E,E,E)-Squalene7683-64-9(E/Z)-Squalene2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-C30H50CAS-111-02-4
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match638072

Attributed physical-property, hazard, environmental and use annotations.

  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) shou Source: CAMEO Chemicals
  • Note: This chemical does not meet GHS hazard criteria for 25.5% (80 of 314) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H304 (73.6%): May be fatal if swallowed and enters airways [Danger Aspiration hazard] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P301+P316, P331, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 314 reports by companies from 3 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 80 of 314 reports by companies.; There are 2 notifications provided by 234 of 314 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H304: May be fatal if swallowed and enters airways [Danger Aspiration hazard] Source: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P301+P316, P331, P405, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
  • Cosmetic Ingredient Review Finding(s): Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org Source: Cosmetic Ingredient Review (CIR)
  • Toxicity Summary: IDENTIFICATION AND USE: Squalene is a liquid. The source of squalene is usually from shark liver and sometimes from olive oil. It is used as traditional medicine, experimental medication, and dietary supplement. Squalene is a component of some adjuvants that are added to vaccines to enhance the immune response. MF59, an adjuvant added to the FLUAD flu vaccine, is such an example. Squalene by itself is not an adjuvant, but emulsions of squalene with surfactants do enhance the immune response. Squalene is also found in a variety of foods, cosmetics. HUMAN EXPOSURE AND TOXICITY: Squalene is not a significant human skin irritant or sensitizer. Limited contact sensitization tests indicate squalene is not a significant contact allergen or irritant. Twenty two million doses of the influenza vaccine FLUAD have been administered safely since 1997. This vaccine contains about 10 mg of squalene per dose. No severe adverse events have been associated with the vaccine. Some mild local reactions have been observed. Clinical studies on squalene-containing vaccines have been done in infants and neonates without evidence of safety concerns. One of the many possible exposures suspected of causing ch Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Bioconcentration: An estimated BCF of 4 was calculated in fish for squalene(SRC), using an estimated log Kow of 14.1(1) and a regression-derived equation(1). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1X10+8(SRC), determined from a structure estimation method(2), indicates that squalene is expected to be immobile mobility in soil(SRC). Volatilization of squalene from moist soil surfaces is expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.0 atm-cu m/mole(SRC), using a fragment constant estimation method(2). However, adsorption to soil is expected to attenuate volatilization(SRC). Squalene is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 6.3X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(1). Using OECD Guideline 301F (Ready Biodegradability: Manometric Respirometry Test), squalene achieved 80.1 and 42.6% degradation at 20 and 100 mg/L, respectively, over 28-day incubation periods classifying the compound as inherently biodegradable, but not readily biodegradable(3). Microorganisms isolated from soil have been able to use squalene as a carbon source(4). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1X10+8(SRC), determined from a structure estimation method(2), indicates that squalene is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is expected(3) based upon an estimated Henry's Law constant of 2.0 atm-cu m/mole(SRC), developed using a fragment constant estimation method(2). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 6 hours and 8 days, respectively(SRC). However, volatilization from water surfaces is expected to be attenuated by adsorption to suspended solids and sediment in the water column. The estimated volatilization half-life from a model pond is >5 years if adsorption is considered(4). According to a classification scheme(5), an estimated BCF of 4(SRC), from an estimated log Kow of 14.1(2) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Using OECD Guideline 301F (Ready Biodegradability: Manometric Respirometry Test), squalene achieved 80.1 and 42.6% degradation at 20 and 100 mg/L, respectively, over 28 Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), squalene, which has an estimated vapor pressure of 6.3X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase squalene is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be about 43 minutes(SRC), calculated from its rate constant of 5.3X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Vapor-phase squalene is also degraded in the atmosphere by reaction with ozone(SRC); the half-life for this reaction in air is estimated to be about 7 minutes(SRC), calculated from its rate constant of 2.6X10-15 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Several studies have found that squalene reacts readily with ozone in indoor air and yields reaction products that include mono- and bifunctional group compounds such as aldehydes, ketones and carboxylic acids(3). Squalene, which is Source: Hazardous Substances Data Bank (HSDB)
  • Cosmetic Ingredient Review Link: CIR ingredient: Squalene Source: Cosmetic Ingredient Review (CIR)
  • Sources/Uses: Present in large quantities in shark liver oil, and in minute amounts in olive oil, wheat germ oil, rice bran oil, and yeast; An intermediate in the biosynthesis of cholesterol; Used as a bactericide, and as an intermediate for pharmaceuticals, organic coloring agents, rubber chemicals, aromatics, and surface active agents; [Merck Index] Also used in biochemical and pharmaceutical research; [NTP] Source: Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
  • Uses: Bactericide; intermediate in manufacture of pharmaceuticals, organic coloring materials, rubber chemicals, aromatics and surface active agents. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Biochemical and pharmaceutical research, a percursor of cholestrol in biosynthesis, chemical intermediate. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Squalane and Squalene have been identified as natural components of human sebum. Both ingredients are used in a variety of cosmetics at concentrations ranging from < or =0.1 to >50%. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Squalene is a polyunsaturated hydrocarbon with a formula of C30H50. Squalene can be found in certain fish oils, especially shark liver oil, in high amounts and some vegetable oils in relatively smaller amounts. Human sebum also contains 13% squalene as one of its major constituents. Squalane is a saturated derivative of squalene and also found in these sources. Interest in squalene has been raised after its characterization in shark liver oil which is used as a traditional medicine for decades. Several studies exhibited results that prove certain bioactivities for squalene and squalane. Up to date, anticancer, antioxidant, drug carrier, detoxifier, skin hydrating, and emollient activities of these substances have been reported both in animal models and in vitro environments. According to promising results from recent studies, squalene and squalane are considered important substances in practical and clinical uses with a huge potential in nutraceutical and pharmaceutical industries. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: For more Uses (Complete) data for Squalene (9 total), please visit the HSDB record page. Source: Hazardous Substances Data Bank (HSDB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision